The relatively low rates of high-grade cytopenia and severe infections, including infections leading to death, observed with these therapies and non-overlapping AE profiles with conventional MM agents may make GPRC5D-targeting bispecific antibodies versatile combination partners. Here, GPRC5D is linked to infection.